Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03765502 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing User Experience of Different Delivery Devices for Glucagon
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT03765502 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 99 participants.
The verdict
NCT03765502, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will last approximately 17 days for Trained Users and Participants with Diabetes (PWD). Part B will last approximately nine (9) days for Untrained Users. Each part will be separated by approximately 7 days.
Interventions
- DEVICE Nasal Glucagon Device (NG)
- DEVICE GEK
- DRUG IM Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2019-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03765502
The ClinicalTrials.gov registry entry for NCT03765502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nasal Glucagon Device (NG) is the first listed.
NCT03765502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03765502 about?
NCT03765502 is a clinical study titled "A Study Comparing User Experience of Different Delivery Devices for Glucagon". The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will...
What is the current status of trial NCT03765502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2018-11-19. Estimated completion is 2019-01-03.
What interventions are being tested in trial NCT03765502?
The interventions under investigation include: Nasal Glucagon Device (NG) (DEVICE), GEK (DEVICE), IM Glucagon (DRUG).
Who is sponsoring clinical trial NCT03765502?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.